AnhCo Nguyen is CEO & President at Atara Biotherapeutics, Inc. (ATRA). They have made 13 open-market trades across 1 company since 2023, most recently 2026-08-17.
CIK 0001977970
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ATRA | 132,775 | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-08-26 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRA | SELL | 2026-08-17 | 2026-08-26 | $8.08 | $41K | +7.9% | -7.6% | — |
| ATRA | SELL | 2026-05-18 | 2026-05-20 | $9.13 | $48K | +6.9% | +13.9% | -10.3% |
| ATRA | SELL | 2026-03-02 | 2026-03-04 | $5.09 | $15K | +9.9% | -8.3% | +87.1% |
| ATRA | SELL | 2025-11-17 | 2025-11-19 | $13.19 | $38K | -12.3% | +23.2% | -67.8% |
| ATRA | SELL | 2025-08-18 | 2025-08-20 | $11.62 | $34K | +6.1% | +3.6% | +15.7% |
| ATRA | SELL | 2025-05-16 | 2025-05-20 | $6.76 | $22K | +17.3% | +16.4% | +68.3% |
| ATRA | SELL | 2025-03-03 | 2025-03-05 | $7.00 | $23K | -0.4% | -22.4% | +16.5% |
| ATRA | SELL | 2024-11-18 | 2024-11-20 | $11.20 | $19K | +18.5% | +6.2% | -24.7% |
| ATRA | SELL | 2024-08-16 | 2024-08-20 | $6.63 | $12K | +4.8% | +9.4% | +56.3% |
| ATRA | SELL | 2024-05-16 | 2024-05-20 | $0.62 | $27K | -19.9% | -49.1% | -58.9% |
| ATRA | SELL | 2024-03-04 | 2024-03-06 | $0.72 | $8K | -17.3% | +7.5% | -21.1% |
| ATRA | SELL | 2023-11-16 | 2023-11-20 | $0.39 | $3K | +17.7% | +0.6% | +52.7% |
| ATRA | SELL | 2023-08-16 | 2023-08-18 | $1.65 | $25K | -2.7% | +4.0% | -68.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.